Drug updated on 4/16/2024
| Dosage Form | Tablet (oral; 50 mg, 100 mg) |
| Drug Class | Kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Jayprica (pirtobrutinib) Prescribing Information. | 2023 | Lilly USA, LLC, Indianapolis, IN |
Randomized Controlled Trials
| Document Title | Sex Distribution | Year | Source |
|---|---|---|---|
| MCL-135 BRUIN MCL-321, a phase 3 open-label, randomized study of pirtobrutinib versus investigator choice of BTK inhibitor in patients with previously treated, BTK inhibitor naïve mantle cell lymphoma (trial in progress). | Data not availableSubjects F: null% M: null% | 2022 | Clinical Lymphoma, Myeloma & Leukemia |
Sex Distribution:
Year:
2022
Source:Clinical Lymphoma, Myeloma & Leukemia